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Abstract: Novel, comprehensive approaches for biomarker discovery and validation are urgently needed. One particular 
area of methodologic need is for discovery of novel genetic biomarkers in complex diseases and traits. Here, we review 
recent successes in the use of genome wide association (GWA) approaches to identify genetic biomarkers in common human 
diseases and traits. Such studies are yielding initial insights into the allelic architecture of complex traits. In general, it 
appears that complex diseases are associated with many common polymorphisms, implying profound genetic heterogeneity 
between affected individuals.
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Introduction
Genetic biomarkers are uniquely important since they are unambiguously associated with causality of 
diseases, traits or phenotypes. In common with other types of biomarkers, they are useful for diagnosis, 
patient stratiﬁ  cation and prognostic or therapeutic categorization. Distinctively, however, they are 
frequently useful for provision of novel insights into disease pathogenesis and, thereby, novel therapeutic 
targets and strategies. Furthermore, inherited genetic biomarkers are present at birth, enabling institu-
tion of timely preventative or ameliorative measures.
During the past 25 years, genetic linkage studies have been exceptionally effective in identifying 
genetic biomarkers in Mendelian (simple or single gene) disorders. These studies have identiﬁ  ed causal 
gene variants in more than 1300 Mendelian diseases (Botstein and Risch, 2003). Most common diseases, 
traits and phenotypes, however, do not exhibit Mendelian patterns of inheritance, but rather exhibit 
complex, multifactorial expression and inheritance. None-the-less, linkage based methods, especially 
the transmission disequilibrium test (Spielman et al. 1993) were developed and applied to a number of 
complex traits in the 1990s. These linkage studies met with little success in the identiﬁ  cation of the 
allelic determinants of these common, complex disorders or traits (Freimer and Sabatti, 2004). In 
particular, there has been a lack of replication among studies, whereby an initial study will identify a 
genotype with large estimated genetic effects (relative risk) but subsequent studies will not corroborate 
the results (Lander and Kruglyak, 1995; Göring et al. 2001). In part, this reﬂ  ects the dependence of 
linkage studies on unusually informative pedigrees (with multiple affected and unaffected individuals), 
which induce a bias toward rare, semi-Mendelian disease subsets in sub-populations. Tremendous 
excitement, therefore, has met recent reports of successful identiﬁ  cation of genetic biomarkers in 
complex traits using an approach that does not have this limitation—genome wide association (GWA) 
studies.
Genome wide association studies are predicated on two observations:
1. The brief history of most human populations precludes sufﬁ  cient number of generations (or meioses) 
to create recombination events (or mutations) between closely linked markers; and
2. Suppression of meiotic recombination (coldspots) occurs very frequently in mammalian genomes.
Thus, approximately 80% of the human genome is comprised of ~10 kilobase regions (haplotype 
blocks, HB) that do not show recombination in human populations (International HapMap Consortium, 
2005). Genetic variants within HB are in linkage disequilibrium (LD). This phenomenon enables much 284
Kingsmore et al
Biomarker Insights 2007:2
of the recombination history in a population to be 
ascertained by genotyping a large set of randomly 
spaced tags throughout the genome, especially if 
these tags are located within HB. During the last 
ten years, more than ten million single nucleotide 
polymorphisms (SNPs) have been aggregated in a 
public database (Sherry et al. 2001). Furthermore, 
the International HapMap project has genotyped 
over three million of these SNPs that are common 
(occur with a minor allele frequency of 5%) in 
human populations and have assembled these 
genotypes computationally into a genome-wide 
map of SNP-tagged HB (International HapMap 
Consortium, 2005). These resources, together with 
array technologies for massively parallel SNP 
genotyping, have made GWA studies feasible. 
Further, the well established epidemiological case-
control experimental design is directly applicable 
to GWA studies.
Initially, association genetic studies (focused on 
candidate genetic loci) also exhibited a lack of 
replication among studies (Ionnidis et al. 2001; 
Hirschhorn et al. 2002). The potential reasons for 
inconsistent results consist of unobserved, 
confounding biological sources of heterogeneity 
including inconsistent or poorly deﬁ  ned measure-
ments of the phenotype, heterogeneous genetic 
sources for the phenotype, population stratiﬁ  cation, 
population-speciﬁ  c LD, heterogeneous genetic and 
epigenetic backgrounds, or heterogeneous envi-
ronmental inﬂ  uences. In addition to these biolog-
ical explanations, there are statistical reasons for 
inconsistent results including failure to control the 
rate of false discoveries, lack of power, model 
misspecification and heterogeneous bias in 
estimated effects among studies (Cardon and Bell, 
2001; Cardon and Palmer, 2003; Redden and 
Allison, 2003; Sillanpää and Auranen, 2004). 
Among these, the most likely source of non-
replication is the lack of power due to the limited 
number of individuals genotyped and phenotyped 
in these experiments (Risch, 2000; Lohmueller 
et al. 2003). In the past year, however, a signiﬁ  cant 
number of studies have been published that have 
used SNP genotyping arrays in large cohorts of 
individuals resulting in replicated associations 
between individual SNP-tagged HB and common, 
complex traits, phenotypes or diseases. In common 
with other biomarker development approaches, 
GWA study designs entail discovery, validation 
and replication stages (Kingsmore, 2006). This 
design is critical for detection of meaningful, 
hypothesis-generating genotype-phenotype 
associations given the large number of comparisons 
involved, prior probability estimates of association, 
sample sizes, resampling procedures, and statistical 
signiﬁ  cance thresholds.
Results of Initial GWA Studies
The ﬁ  rst GWA study, published in 2002, examined 
myocardial infarction (Ozaki et al. 2002). The 
discovery phase comprised genotyping of 65,671 
informative, coding domain SNPs (cSNPs) in 752 
cases and control individuals (Table 1). Gene-
tagging SNPs are more informative than random 
SNPs, since the vast majority of true-positive 
associations will be with genes (Botstein and 
Risch, 2003). The validation phase featured 26 
SNPs and 2137 individuals and confirmed an 
association with a 50 kb HB containing the 
lymphotoxin-α (LTA), nuclear factor of kappa light 
polypeptide gene enhancer in B cells, inhibitor-like 
1 (NFKBIL1) and HLA-B associated transcript 1 
(BAT1) genes (Table 2). Replication studies have 
subsequently been undertaken, some of which have 
conﬁ  rmed association of this region to myocardial 
infarction-related phenotypes, and, in particular, 
to a nonsynonymous SNP (nsSNP) in LTA 
(Yamada et al. 2004; Laxton et al. 2005; Mizuno 
et al. 2006; Clarke et al. 2006; Kimura et al. 2007; 
Sedlacek et al. 2007; Koch et al. 2007). As with 
most GWA studies, the association of LTA with 
myocardial infarction was an unexpected ﬁ  nding 
and suggests novel therapeutic approaches.
A second, pioneering GWA study examined age-
related macular degeneration (AMD) (Klein et al. 
2005, Table 1). The discovery phase genotyped 
105,980 SNPs in only 146 cases and control 
individuals. SNPs in the complement factor H (CFH) 
gene, including an nsSNP, showed significant 
association with AMD. A validation phase was not 
performed, but numerous subsequent studies have 
replicated associations of CFH variants with protection 
and predisposition to AMD (Zareparsi et al. 2005; 
Hageman et al. 2005; Souied et al. 2005; Magnusson 
et al. 2006). Of all complex traits examined by GWA 
to date, AMD is unique in that a single, novel HB 
explained 61% of the genetic variance, conferring an 
odds ratio (OR) of 7.4 (Table 2). To put this in 
perspective, this OR is of similar magnitude to the 
classic associations of HLA-B27 with anterior uveitis/
ankylosing spondylitis and HLA alleles with type 1 
diabetes mellitus. Complement pathway dysregulation 
was a novel, unexpected association with AMD. 285
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Excitingly, this defect is likely to be therapeutically 
tractable.
During 2006, considerable technical and 
cost-effectiveness challenges were overcome, 
resulting in broad adoption and numerous GWA 
study publications.
Five large GWA studies have examined Crohn’s 
disease and ulcerative colitis, the two most common 
types of inﬂ  ammatory bowel disease (IBD) (Table 
1). Three of the studies used microarrays featuring 
~300,000 random SNPs (Duerr et al. 2006; Rioux 
et al. 2007; Libioulle et al. 2007), while the fourth 
study used custom chips featuring ~16,000 non-
synonymous SNPs (Hampe et al. 2007). The behe-
moth ﬁ  fth study used 469,557 random SNPs in 
14,000 individuals with seven common diseases but 
lacked replication (WTCCC 2007). Of 14 novel HB 
associations, 10 were unique to a single study. Three 
HB were concordant in four of the ﬁ  ve studies 
(representing the genes CARD15, IL23R and 
ATG16L1). One HB was identiﬁ  ed in two of the 
ﬁ  ve studies (PTGER4). Estimated genetic effects, 
i.e. relative risks, of associated loci were small; the 
cumulative odds ratio associated with 28 risk alleles 
was only 1.45. Several studies sought evidence for 
epistatic interactions between IBD-associated HB. 
Two studies found suggestive evidence for epistasis 
involving two different pairs of HB. As yet, IBD 
candidate genes do not appear to be coalescing into 
biologic networks or pathways.
Six large GWA studies have examined type II (or 
adult onset) diabetes mellitus (T2DM), providing 
the best example to date of capabilities and limita-
tions of GWA studies (Diabetes Genetics Initiative, 
Broad Inst. et al. 2007; Scott et al. 2007; Sladek et 
al. 2007; Steinthorsdottir et al. 2007; Zeggini et al. 
2007; WTCCC 2007; Table 1). The discovery phase 
of these studies comprised genotyping of 313,179–
469,557 SNPs in 2,335–16,179 individuals. Several 
studies sought association both with SNPs and with 
haplotype blocks in the discovery phase. Many of 
these studies were very large. Case-control and 
family-based association statistics were employed 
in most of the studies. Two employed over 9,000 
individuals in the validation phase while one lacked 
replication.
Concordance of associated genes between 
T2DM GWA studies was striking; of 10 novel HB 
associations, only two were unique to a single 
study. Discordance of associations partly reﬂ  ected 
different coverage of speciﬁ  c HB by the two 
microarray platforms used for genotyping. In 
common with IBD, T2DM-associated HB 
exhibited small estimated genotypic effect sizes. 
In contrast to IBD, however, many of the 
T2DM-associated candidate genes coalesced into 
biologic pathways, such as pancreatic islet beta 
cell function, including insulin biosynthesis.
Three studies performed initial modeling of 
how loci combine to affect susceptibility to T2DM. 
One study found suggestive evidence for epistatic 
interactions between two HB. Otherwise, it 
appeared that T2DM ﬁ  ts a polygenic threshold 
model with additive/multiplicative effects of indi-
vidual loci.
As anticipated, allele frequencies showed 
considerable variation between ethnic and racial 
groups. Somewhat surprising, however, was the 
incidence of conservation of T2DM and IBD 
associated risk alleles between independent 
populations. 
Two studies extended GWA analysis of T2DM 
to endophenotypes related to serum triglycerides 
and obesity (Diabetes Genetics Initiative, Broad 
Inst. et al. 2007; Frayling et al. 2007; Table 1). For 
example, one gene associated with T2DM, fat mass 
and obesity associated gene (FTO) (Scott et al. 
2007), also showed an association with obesity-
associated quantitative traits in an independent 
study (Frayling et al. 2007). Frayling et al. exam-
ined the association of the FTO variant with body 
mass index (BMI) in 13 cohorts with 38,759 
participants. The association of FTO SNPs with 
obesity has been independently conﬁ  rmed in 8000 
individuals (Dina et al. 2007). 
Cancers are fascinating genetic diseases as 
they feature the combined effects of germline 
risk alleles and multiple somatic mutations. 
Three GWA studies sought inherited haplotype 
block associations with breast cancer (Easton 
et al. 2007; Stacey et al. 2007; Hunter et al. 
2007). The discovery phase of these studies 
comprised genotyping of 227,876–528,173 
SNPs in 2,287–13,163 individuals. Validation 
phases varied in size from 3,848–44,438 indi-
viduals. Associations were identified in SNPs 
in FGFR2 (two studies), TNRC9 (two studies), 
at haplotype blocks rs13387042 and rs3817198 
(which do not contain known genes, one study 
each), MAP3K1 (one study) and LSP1 (one 
study). 
Two GWA studies sought association signals 
in prostate cancer (Gudmundsson et al. 2007; 
Yeager et al. 2007). The discovery phase of these 288
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studies comprised genotyping of 316,515–550,00 
SNPs in 2,339–4,517 individuals. Validation 
phases varied in size from 3,655–6,266 individ-
uals. An association with a HB at 8q24 that had 
previously been identiﬁ  ed by linkage analysis 
(Amundadottir et al. 2006) was seen in both 
studies. In addition, both studies identiﬁ  ed a 
second 8q24 HB, ~300 kb upstream from the ﬁ  rst. 
As yet, the functional basis of these associations 
is unclear. While individual 8q24 variants showed 
modest estimated genetic effects, the cumulative 
effect of several variants ﬁ  ts a multiplicative 
model that conferred a population attributable risk 
(PAR), the expected reduction in prostate cancer 
incidence if the risk alleles did not exist in the 
population, of up to 68% (Haiman et al. 2007).
The applicability of GWA studies to complex 
traits has also been demonstrated. One study 
undertook GWA with numerous quantitative and 
categorical memory-associated endophenotypes 
(Papassotiropoulos et al. 2006). Despite the 
small size of the discovery cohort (341 indi-
viduals), associations with one HB (in the 
KIBRA gene) were replicated in two validation 
cohorts (totaling 680 individuals). A notable 
strength of this study was that associations were 
sought with multiple types of endophenotypes 
(performance in seven memory-associated tests 
and functional magnetic resonance image-based 
measures of the hippocampus during three 
memory-associated tests).
In addition to the identification of novel HB 
associations, GWA studies have confirmed 
several associations of susceptibility genes that 
were previously established by linkage analysis 
in large pedigrees. For example, a GWA study 
of 502,627 SNPs in 1086 cases of late-onset 
Alzheimer’s disease and controls verified the 
well established APOE susceptibility gene 
(Coon et al. 2007).
A remaining problem with large GWA studies 
is genotyping cost. One innovative study provided 
evidence that sample pooling strategies may be 
effective. In a GWA study of bipolar disorder, 
investigators created 39 pools, each containing 
equimolar amounts of DNA from 42–80 individuals 
(Baum et al. 2007). These pools represented a 
discovery and replication cohort. Pools were indi-
vidually genotyped for 555,235 SNPs and normal-
ized allele frequencies were inferred from intensity 
data. Replicates were assayed for each pool. 37 
SNPs showing allele frequency differences in both 
cohorts were individually genotyped and 76% 
retained signiﬁ  cant associations. 
Conclusions
During the past year, the utility of GWA studies for 
identiﬁ  cation of novel genomic associations with 
complex disorders has unambiguously been estab-
lished. In general these studies have employed large 
case-control cohorts featuring both familial and 
sporadic cases, categorical trait deﬁ  nitions and up 
to half a million commonly polymorphic SNPs. 
Excitingly, these studies are starting to provide 
empiric data to resolve decades of debate about the 
genetic architecture of complex traits. To date, with 
the exception of CFH in AMD, the estimated genetic 
effects of replicated associations have been 
uniformly and surprisingly small (Table 2). Also 
surprising is the high frequency of many risk alleles, 
albeit this may reﬂ  ect an artifact induced by use of 
genotyping arrays that primarily feature common 
polymorphisms (Table 3). Informed by studies to 
date, the picture of the genetic architecture of 
complex traits that is emerging is immense poly-
genicity and individual genetic heterogeneity. In 
general, the data ﬁ  t additive, threshold models. In a 
handful of informative studies, little evidence for 
epistasis has been observed. If conﬁ  rmed, an impli-
cation will be that genetic diagnostics are still a long 
way off and will certainly not result in the determin-
istic prognostications portrayed in the 1997 movie 
Gattaca.
Encouragingly, most associated haplotype blocks 
are small enough to feature a single gene (Table 3). 
In large measure, this reflects the use of more 
outbred populations in ﬁ  ne-mapping validation 
phases. Furthermore, many HB contain a single, 
unequivocally functional variant. The distribution 
of variants does not yet show much difference from 
causal variants identiﬁ  ed in Mendelian disorders. 
Thus, nsSNPs are relatively common and rSNPs are 
uncommon, a controversial point (Botstein and 
Risch, 2003; Knight, 2005; Thomas and Kejariwal, 
2004). The vast majority of associated genes 
identified to date were not candidate genes 
previously, continuing the marvelous tendency of 
comprehensive, genetic-driven studies to be 
hypothesis-informing. It is refreshing to see 
associations with genes that had never previously 
been considered in a disease or trait. As yet, the 
confluence of associated genes into biologic 
networks and pathways has been disappointing. 290
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Surprisingly, there appears to be significant 
conservation of variant associations between human 
populations (albeit in the setting of frequently 
different allele frequencies). The emerging, principal 
beneﬁ  t of GWA studies may therefore be elucidation 
of molecular mechanisms underpinning poorly 
understood diseases and traits.
In the few informative studies reported to date, 
endophenotypes have been highly instructive in 
dissecting the network or pathway perturbed by an 
individual variant to impact a complex trait. It is 
particularly exciting to see the application of multi-
mode endophenotypes, such as combinations of 
psychological testing, brain imaging and gene 
expression in one study (Papassotiropoulos et al. 
2006). The very large cohorts needed to discover 
and validate variants with small effect sizes 
preclude the collection of rich, accurate metadata. 
It is likely that future studies will utilize much 
greater stratiﬁ  cation of traits than the phenotypi-
cally crude studies reported to date. Recent GWA 
studies of breast cancer provide a good example 
of the added genetic complexity that can be 
revealed by trait stratiﬁ  cation (Easton et al. 2007; 
Hunter et al. 2007; Stacey et al. 2007). In addition, 
following replication of associations with categor-
ical traits, it is anticipated that targeted genotypic 
examination of many endophenotypes will be 
highly instructive in the dissection of disease 
pathogenesis.
Future Developments 
and Implications
Several trends observed in GWA studies to date are 
anticipated to continue. One million SNP chips are 
about to be launched and genotype accuracies have 
improved. Cohort sizes are increasing. Combinations 
of genotype-based and haplotype-based associations 
are becoming more prevalent. Experimental designs 
and statistical methods are becoming more uniform, 
enabling more meaningful meta-analyses. In partic-
ular, the emergence of adaptive designs and the use 
of Bayesian inferential methods produce probabilistic 
synthesis from combined analysis (Barry, 2005). 
Importantly, this will provide an intuitive framework 
for combining information from multiple studies 
resulting in more effective utilization of patient infor-
mation from translational research—especially for 
detection and validation of weak associations.
As noted above, phenotypes remain crude and 
the use of endophenotypes or component pheno-
types is anticipated to increase signiﬁ  cantly. In 
particular, biomarker phenotypes are anticipated 
to become widely used. These are likely to include 
gene expression, proteomic, metabolomic and 
imaging biomarkers. As determinants of complex 
traits are identiﬁ  ed, genetic stratiﬁ  cation of cases 
and controls will be possible, reducing the genetic 
complexity of the trait and enabling identiﬁ  cation 
of additional association signals. An area of 
substantial interest for the pharmaceutical industry 
will be GWA studies of drug response that identify 
patient stratiﬁ  cation markers for clinical trials and 
guide drug improvement, particularly for avoid-
ance of adverse events.
Despite the current euphoria, GWA studies are 
likely to have signiﬁ  cant limitations. Insufﬁ  cient 
numbers of cases will be available for GWA of 
uncommon traits or diseases. Current GWA geno-
typing methods will not identify associations with 
rare variants, even with large effect sizes. Approx-
imately twenty percent of the genome represents 
recombinational hotspots that are not amenable to 
LD-based approaches (International HapMap 
Consortium 2005). At recombinational coldspots, 
haplotype blocks may be too large for unambiguous 
identiﬁ  cation of causal variants. The extent of the 
effect of copy number variation (CNV) on asso-
ciation signals is not yet clear. For some common 
traits or diseases, these considerations may reﬂ  ect 
a substantial proportion of the genetic variance. 
The addition of gene expression proﬁ  ling, CNV 
estimation and large-scale resequencing technolo-
gies to GWA studies should circumvent some of 
these limitations. Use of adaptive statistical 
methods and resampling strategies may circumvent 
the need for thousands of affected individuals in 
uncommon traits (Berry, 2004).
Clearly a huge amount of genetics, biochemistry 
and cell biology remains to be done to conﬁ  rm 
the biologic relevance of associations and to 
elucidate the mechanisms of genotype-phenotype 
associations. For geneticists, a long term goal is to 
piece together the genetic architecture of complex 
traits, evaluating with much greater precision the 
genetic model and contributions of factors such 
as epistasis, genocopies, phenocopies and 
penetrance.
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